Study S000576

A Trial Investigating the Effect of Subcutaneous Semaglutide on Liver Fibrosis Assessed by Magnetic Resonance Elastography in Subjects With Non-alcoholic Fatty Liver Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03357380
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 67
Start: 2017-11-28
Primary completion: 2020-03-20
Lead sponsor: Novo Nordisk A/S
Conditions: Hepatobiliary Disorders; Non-alcoholic Fatty Liver Disease
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2017-001193-42; OTHER:U1111-1194-3900; NIH:2017

Registered primary outcomes

Change in liver stiffness (kPa) assessed by magnetic resonance elastography (MRE) [Up to day -20, week 48]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011424	Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials. Armstrong MJ, Diabetes, obesity & metabolism	2025	Randomized trial	PMID 39609879 DOI	cites ClinicalTrials.gov:NCT03357380
R0049133	The Effect of Semaglutide on Kidney Function: Post Hoc Analysis of Three Randomized Controlled Trials in Non-Alcoholic Fatty Liver Disease Katherine R. Tuttle, Journal of the American Society of Nephrology	2022	Randomized trial	DOI	cites ClinicalTrials.gov:NCT03357380
R0011165	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Flint A, Alimentary pharmacology & therapeutics	2021	Randomized trial	PMID 34570916 DOI	cites ClinicalTrials.gov:NCT03357380; registry reference RESULT:34570916